40 completed, 14 recruiting, 13 terminated, 7 active not recruiting. 87 Phase 1, 25 Phase 2.
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | University of California, Davis | 20 | 2026-09-01 | 2026-08-12 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose) - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2026-08-05 | 2026-11-04 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2026-04-01 | 2026-05-15 | |
| Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-03-24 | 2026-09-16 |
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
| CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Suspended | Thomas Martin, MD | 30 | 2026-02-28 | 2026-06-11 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM DC/MM Fusion Vaccine, GM-CSF - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2026-01-30 | 2026-05-08 |
| Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma Talquetamab, Ciltacabtagene Autoleucel - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 31 | 2025-12-02 | 2026-01-05 |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Talquetamab, Iberdomide, Dexamethasone - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Alfred Chung, MD | 32 | 2025-07-28 | 2026-03-13 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Iberdomide, Belantamab Mafodotin, Dexamethasone - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Alliance for Clinical Trials in Oncology | 88 | 2025-04-23 | 2026-10-02 |
| SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Roswell Park Cancer Institute | 15 | 2025-04-10 | 2026-08-13 |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Recruiting | David Avigan | 25 | 2025-01-31 | 2026-05-07 |
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Terminated | University of Washington | 1 | 2024-12-18 | 2025-07-29 |
| Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 26 | 2024-12-06 | 2026-10-27 |
| ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Elotuzumab, Iberdomide, Dexamethasone - Myeloma, Multiple Myeloma | Phase 1 | Recruiting | Omar Nadeem, MD | 24 | 2024-11-01 | 2026-11-02 |
| Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma OPN-6602, Dexamethasone - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Opna Bio LLC | 130 | 2024-08-22 | 2026-10-30 |
Showing 20 of 87. Sign in to see all of them.
Multiple Myeloma (87) · Leukemia, Lymphocytic, Chronic, B-Cell (15) · Lymphoma, Follicular (14) · Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, Mantle-Cell (14) · Burkitt Lymphoma (13) · Lymphoma, Non-Hodgkin (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Lymphoma, B-Cell, Marginal Zone (12) · Waldenstrom Macroglobulinemia (12) · Lymphoma, Large-Cell, Immunoblastic (11) · Hodgkin Disease (10) · Lymphoma, Large-Cell, Anaplastic (10) · Lymphoma, Extranodal NK-T-Cell (9) · Lymphoma, T-Cell, Cutaneous (9)
Blood Protein Disorders (87) · Cardiovascular Diseases (87) · Hemic and Lymphatic Diseases (87) · Hemorrhagic Disorders (87) · Hemostatic Disorders (87) · Immune System Diseases (87) · Immunoproliferative Disorders (87) · Lymphoproliferative Disorders (87) · Neoplasms by Histologic Type (87) · Paraproteinemias (87) · Vascular Diseases (87) · Hematologic Diseases (86) · Neoplasms (85) · Neoplasms, Plasma Cell (82) · Pathologic Processes (22)
Dexamethasone (25) · Calcium Dobesilate (19) · Biopsy (13) · Bortezomib (12) · Cyclophosphamide (11) · Lenalidomide (11) · carfilzomib (10) · Magnetic Resonance Spectroscopy (9) · Specimen Handling (9) · fludarabine phosphate (9) · auricularum (8) · dexamethasone 21-phosphate (8) · dexamethasone acetate (8) · Whole-Body Irradiation (7) · Cyclosporine (6)
National Cancer Institute (NCI) (21) · Fred Hutchinson Cancer Center (7) · Mayo Clinic (6) · Case Comprehensive Cancer Center (3) · City of Hope Medical Center (3) · Medical College of Wisconsin (3) · Dana-Farber Cancer Institute (2) · David Avigan (2) · Genentech, Inc. (2) · Roswell Park Cancer Institute (2) · Thomas Martin, MD (2) · University of Washington (2) · Abdullah Khan (1) · Actinium Pharmaceuticals (1) · Alfred Chung, MD (1)
United States (77) · Italy (4) · China (3) · Germany (3) · Australia (2) · Denmark (2) · Belgium (1) · France (1) · New Zealand (1) · Norway (1) · Spain (1) · Switzerland (1)
David Maloney (3) · Anupama Kumar, MD (2) · Binod Dhakal, MD (2) · Jacalyn Rosenblatt, MD (2) · Shaji K. Kumar, M.D. (2) · Shaji Kumar (2) · Vivek Roy, M.D. (2) · Abdullah M Khan, MBBS, MSc (1) · Alan Lichtenstein (1) · Alexander K. Stewart, M.D. (1) · Alexander Stewart (1) · Alfred Chung, MD (1) · Amir Mortazavi, MD (1) · Amrita Krishnan (1)
PMID 32499241, PMID 18974373, PMID 19182205, PMID 22259028, PMID 23887852, PMID 24241210, PMID 24474568, PMID 26331432, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28684537, PMID 30562587, PMID 31124580, PMID 33476575, PMID 33492438, PMID 36656461, PMID 39828738
P01CA078902 (3), P30CA015704 (3), P30CA016058 (3), U01CA062502 (3), U01CA062505 (3), U01CA076576 (3), U01CA062487 (2), U01CA062491 (2), U01CA069912 (2), U01CA099168 (2), UM1CA186691 (2), 2019 (1), N01CM00070 (1), N01CM62203 (1), N01CM62204 (1)